Plain Language Summary
-
As the prevalence and associated costs of diabetes increase, choosing cost-effective treatments is becoming ever more important.
-
Studies have shown that early, multifactorial treatments that improve glycemic control and body weight reduce the risk of long-term diabetes-related complications.
-
In the SUSTAIN clinical trial program, once-weekly semaglutide was associated with improved efficacy versus dulaglutide and exenatide extended-release (ER), while in a network meta-analysis, semaglutide was associated with improved efficacy versus liraglutide and lixisenatide in terms of greater HbA1c reductions and weight loss in patients with type 2 diabetes.
-
The present analysis used a clinical treatment approach to assess the long-term cost-effectiveness of semaglutide versus all available GLP-1 receptor agonists for the treatment of patients with type 2 diabetes not achieving glycemic control on oral anti-diabetic medications from a healthcare payer perspective in Denmark.
-
Semaglutide 0.5 mg and 1 mg were associated with improved life expectancy and quality-adjusted life expectancy versus all comparators over the 50 years of the analysis. Semaglutide 0.5 mg was associated with delayed treatment intensification by between 1 and 4 years, reduced costs versus dulaglutide, liraglutide 1.8 mg and lixisenatide, and increased costs versus exenatide ER and liraglutide 1.2 mg, while semaglutide 1 mg was associated with delayed intensification by between 3 and 6 years and reduced costs versus all comparators over patient lifetimes.
-
Both semaglutide doses therefore offer highly cost-effective alternatives to dulaglutide, exenatide ER, liraglutide and lixisenatide for the treatment of patients with type 2 diabetes in Denmark.
Introduction
Methods
Model Overview
Clinical Data for the Primary Analysis
Parameter | SUSTAIN 7 | SUSTAIN 3 | NMA | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Semaglutide 0.5 mg | Semaglutide 1 mg | Dulaglutide 1.5 mg | Semaglutide 1 mg | Exenatide ER | Semaglutide 0.5 mg | Semaglutide 1 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Lixisenatide | |
Physiological parameters, means (standard errors) | ||||||||||
HbA1c (%) | − 1.51 (0.06) | − 1.78 (0.06)* | − 1.37 (0.06) | − 1.54 (0.06)* | − 0.92 (0.06) | − 1.23 (0.13)¤,‡ | − 1.47 (0.12)¤,†,‡ | − 0.87 (0.12) | − 1.11 (0.10) | − 0.56 (0.20) |
Systolic blood pressure (mmHg) | − 2.44 (0.76) | − 4.88 (0.77) | − 2.86 (0.75) | − 4.60 (0.68)* | − 2.23 (0.70) | − 5.41 (1.55) | − 6.28 (1.52)†,‡ | − 4.45 (1.39) | − 4.21 (1.36) | − 3.00 (1.93) |
Diastolic blood pressure (mmHg) | − 0.57 (0.48) | − 2.05 (0.49)* | − 0.03 (0.47) | − 1.00 (0.45) | − 0.10 (0.46) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Total cholesterol (mmol/l) | − 0.18 (0.04) | − 0.14 (0.05) | − 0.07 (0.05) | − 0.24 (0.04) | − 0.15 (0.05) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
HDL cholesterol (mmol/l) | − 0.01 (0.01)* | 0.02 (0.01) | 0.02 (0.01) | 0.02 (0.01) | 0.00 (0.01) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
LDL cholesterol (mmol/l) | − 0.08 (0.04) | − 0.01 (0.04) | 0.02 (0.04) | − 0.12 (0.04) | − 0.09 (0.04) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Triglycerides (mmol/l) | − 0.16 (0.03) | − 0.25 (0.03) | − 0.19 (0.03) | − 0.28 (0.04)* | − 0.05 (0.04) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
BMI (kg/m2) | − 1.63 (0.10)* | − 2.33 (0.10)* | − 1.08 (0.10) | − 2.01 (0.10)* | − 0.65 (0.10) | − 0.86 (0.10)¤,‡ | − 1.35 (0.10)¤,†,‡ | − 0.64 (0.10) | − 0.73 (0.09) | − 0.32 (0.18) |
Estimated glomerular filtration rate (ml/min/1.73 m2) | − 2.42 (0.48) | − 2.80 (0.49) | − 3.51 (0.47) | − 5.83 (0.76) | − 5.27 (0.76) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Hypoglycemia event rates, per 100 patient-years | ||||||||||
Non-severe hypoglycemia | 1.28 | 2.60 | 1.26 | 9.66 | 11.27 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Severe hypoglycemia | 0.00 | 0.43 | 0.84 | 0.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Proportion of non-severe events that are nocturnal | 0.00 | 0.00 | 0.00 | 0.10 | 0.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Proportion of severe events that are nocturnal | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Clinical Data for the Supporting Analyses
Treatment Effects, Biomarker Progression and Treatment Duration
Costs and Utilities
Sensitivity Analyses Conducted for the Primary Analysis
Compliance with Ethics Guidelines
Results
Primary Base Case Analysis
Health outcomes | Semaglutide 0.5 mg | Dulaglutide 1.5 mg | Difference |
---|---|---|---|
Discounted life expectancy (years) | 14.27 (0.19) | 14.24 (0.20) | + 0.03 |
Discounted quality-adjusted life expectancy (QALYs) | 9.19 (0.12) | 9.08 (0.12) | + 0.11 |
Discounted direct costs (DKK) | 415,200 (10,048) | 415,489 (9722) | − 289 |
ICER for semaglutide 0.5 mg versus dulaglutide 1.5 mg | Semaglutide 0.5 mg dominant |
Health outcomes | Semaglutide 1 mg | Dulaglutide 1.5 mg | Difference |
---|---|---|---|
Discounted life expectancy (years) | 14.39 (0.20) | 14.24 (0.20) | + 0.15 |
Discounted quality-adjusted life expectancy (QALYs) | 9.41 (0.12) | 9.08 (0.12) | + 0.34 |
Discounted direct costs (DKK) | 402,073 (9719) | 415,489 (9722) | − 13,416 |
ICER for semaglutide 1 mg versus dulaglutide 1.5 mg | Semaglutide 1 mg dominant |
Sensitivity Analyses
Analysis | Discounted quality-adjusted life expectancy (QALYs) | Discounted direct costs (DKK) | ICER (DKK per QALY gained) | ||||
---|---|---|---|---|---|---|---|
Semaglutide 1 mg | Dulaglutide 1.5 mg | Difference | Semaglutide 1 mg | Dulaglutide 1.5 mg | Difference | ||
Base case | 9.41 | 9.08 | + 0.34 | 402,073 | 415,489 | − 13,416 | Semaglutide dominant |
20-year time horizon | 8.17 | 7.88 | + 0.28 | 295,697 | 306,919 | − 11,222 | Semaglutide dominant |
10-year time horizon | 5.48 | 5.28 | + 0.20 | 152,959 | 167,743 | − 14,785 | Semaglutide dominant |
Statistically significant differences only | 9.40 | 9.08 | + 0.32 | 403,334 | 415,489 | − 12,156 | Semaglutide dominant |
First treatment intensification at HbA1c ≥ 7.0% and second intensification at HbA1c ≥ 7.5% | 9.16 | 8.88 | + 0.28 | 427,307 | 438,257 | − 10,950 | Semaglutide dominant |
First treatment intensification at HbA1c ≥ 8.0% and second intensification at HbA1c ≥ 8.5% | 9.59 | 9.24 | + 0.34 | 383,083 | 390,248 | − 7165 | Semaglutide dominant |
Treatment intensification at 3 years | 9.65 | 9.54 | + 0.11 | 386,173 | 382,932 | + 3242 | 30,408 |
Treatment intensification at 5 years | 9.72 | 9.60 | + 0.12 | 375,320 | 371,568 | + 3753 | 31,721 |
GLP-1 receptor agonist treatment continued for patient lifetimes | 9.45 | 9.08 | + 0.37 | 476,223 | 502,717 | − 26,494 | Semaglutide dominant |
Cost of complications + 25% | 9.41 | 9.08 | + 0.34 | 436,659 | 454,138 | − 17,479 | Semaglutide dominant |
Cost of complications − 25% | 9.41 | 9.08 | + 0.34 | 367,496 | 376,849 | − 9353 | Semaglutide dominant |
All costs + 25% | 9.41 | 9.08 | + 0.34 | 499,312 | 516,115 | − 16,803 | Semaglutide dominant |
All costs − 25% | 9.41 | 9.08 | + 0.34 | 304,842 | 314,872 | − 10,030 | Semaglutide dominant |
Lee et al. BMI disutility applied | 8.96 | 8.57 | + 0.40 | 402,073 | 415,489 | − 13,416 | Semaglutide dominant |
Evans et al. hypoglycemia disutilities applied | 9.30 | 8.94 | + 0.37 | 402,073 | 415,489 | − 13,416 | Semaglutide dominant |
Currie et al. hypoglycemia disutilities applied | 9.49 | 9.17 | + 0.32 | 402,073 | 415,489 | − 13,416 | Semaglutide dominant |
Supporting Analyses
Health outcomes | Semaglutide 1 mg | Exenatide ER | Difference |
---|---|---|---|
Discounted life expectancy (years) | 14.79 (0.18) | 14.55 (0.20) | + 0.24 |
Discounted quality-adjusted life expectancy (QALYs) | 9.46 (0.12) | 8.98 (0.12) | + 0.47 |
Discounted direct costs (DKK) | 461,487 (10,962) | 479,575 (11,829) | − 18,088 |
ICER for semaglutide 1 mg versus exenatide ER | Semaglutide 1 mg dominant |
Health outcomes | Semaglutide 0.5 mg | Semaglutide 1 mg | Exenatide ER | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Lixisenatide |
---|---|---|---|---|---|---|
Discounted life expectancy (years) | 14.16 (0.21) | 14.26 (0.19) | 14.07 (0.21) | 14.04 (0.20) | 14.12 (0.20) | 13.98 (0.19) |
Discounted quality-adjusted life expectancy (QALYs) | 8.94 (0.13) | 9.14 (0.12) | 8.75 (0.13) | 8.73 (0.12) | 8.80 (0.12) | 8.55 (0.12) |
Discounted direct costs (DKK) | 431,248 (10,024) | 416,147 (9771) | 428,031 (10,687) | 429,730 (9883) | 462,218 (10,721) | 448,210 (11,094) |
ICER for semaglutide 0.5 mg (DKK per QALY gained) | – | – | 17,024 | 7390 | Semaglutide 0.5 mg dominant | Semaglutide 0.5 mg dominant |
ICER for semaglutide 1 mg (DKK per QALY gained) | – | – | Semaglutide 1 mg dominant | Semaglutide 1 mg dominant | Semaglutide 1 mg dominant | Semaglutide 1 mg dominant |